期刊文献+

子痫前期患者与正常妊娠孕妇羊水差异蛋白质谱分析 被引量:2

Analysis of differential protein mass spectrogram in the amniotic fluid of pre-eclampsia and normal pregnancy
原文传递
导出
摘要 目的 探讨并初步筛选子痫前期患者的特异性羊水标志物。方法 利用CM10蛋白芯片和表面增强激光解析离子化飞行时间质谱(SELDI TOF MS)技术,检测8例重度子瘌前期患者(研究组)和8例晚孕期正常孕妇(对照组)羊水中差异蛋白质的相对含量。并在8例中孕期(孕20±周)正常孕妇(中孕组)羊水中寻找有无这些差异蛋白的存在及其含量变化情况。结果 (1)研究组与对照组羊水蛋白质在相对分子质量/电荷比值(质/荷比)2000-50000范围内,有4种不同质荷比蛋白质的相对含量有明显差异。(2)研究组质荷比为4653的蛋白质相对含量[(1.52±0.71)%]明显低于对照组[(3.16±1.64)%](P〈0.05),而质荷比为3841、8520、8579的蛋白质相对含量分别为(7.02±4.37)%、(3.74±1.96)%、(5.09±1.93)%,均高于对照组[(2.58±1.09)%、(1.83±0.67)%、(3.06±1.57)%,P均〈0.05]。(3)中孕组羊水中可以找到这四种差异蛋白质。结论 子痫前期患者与正常孕妇羊水蛋白质质谱存在明显差异。有4种不同质荷比相对应的蛋白质可能是子痫前期患者羊水特异性的生物标志物。 Objective To investigate the specific biomarker in amniotic fluid of pre-eclampsia. Methods The relative amount of differential proteins were detected in amniotic fluid of 8 cases of severe pre-eclampsia (study group) and 8 cases of normal pregnancy in late trimester (control group) by CM10 proteinchip array and surface enhanced laser desorption/ionization time of flight mass spectroscopy(SELDI TOF MS) to see whether there were differential proteins and to study the variances of contents in the amniotic fluid of 8 cases of normal pregnancy in mid trimester (mid pregnancy group). Results (1)Significant differences were found of relative amount of 4 kinds of proteins of different mass/zharge ratio within 2000-50 000 between the study and control group. (2) The relative amount [(1.52±0.71) %] of the protein with mass/zharge ratio of 4653 in the study group was much lower, than that of control[(3. 16±1.64)%] (P〈0.05). While the relative amount[ (7. 02±4. 37)%, (3.74±1.96)% ,(5.09±1.93)% ]of the proteins which had a mass/zharge ratio of 3841,8520,8579 were higher than those of control[ (2.58±1.09)%,(1.83±0. 67)%,(3.06±1.57)%](P〈0.05). (3) Four differential kinds of proteins were found in the mid pregnancy group. Conclusions There are significant difference in the protein mass spectrogram in the amniotic fluid between pre-eclampsia and normal pregnancy. Four different kinds of proteins with different mass/zharge ratio may be the specific biomarkers in the amniotic fluid of pre-eclampsia.
出处 《中华围产医学杂志》 CAS 2007年第5期293-296,共4页 Chinese Journal of Perinatal Medicine
基金 国家自然基金重点课题(30530760)
关键词 先兆子痫 妊娠 羊水 光谱法 质量 基质辅助激光解吸电离 蛋白质类 Pre-eclampsia Pregnancy Amniotic fluid Spectrometry, mass, matrix-assisted laser desorption-ionization Proteins
  • 相关文献

参考文献16

  • 1Ruetschi U, Rosen A, Karlsson G, et al. Proteomic analysis using protein chips to detect biomarkers in cervical and amniotic fluid in women with intra-amniotic inflammation. J Proteome Res, 2005,4 : 2236-2242.
  • 2Buhimschi IA, Christner R, Buhimschi CS. Proteomic biomarker analysis of amniotic fluid for identification of intra-amniotic inflammation. BJOG, 2005,112:173-181.
  • 3Thadikkaran L, Crettaz D, Siegenthaler MA, et al. The role of proteomics in the assessment of premature rupture of fetal membranes. Clinica Chimica Acta, 2005,360 : 27-36.
  • 4Wasinger VC,Cordwen SJ,Cerpa-poljak A, et al. Progress with gene-product mapping of the Mollicutes Mycoplasma genitalium. Electrophoresis, 1995,16 : 1090-1094.
  • 5Chapman K. The proteinchip biomarker system from ciphergen biosystems: a novel proteomics platform for rapid biomarker discovery and validation. Biochem Soc Trans, 2002,30 : 82-87.
  • 6余捷凯,郑树,唐勇,李力,胡跃,刘建.血清蛋白质谱与人工神经网络模型诊断卵巢癌的应用性研究[J].中华检验医学杂志,2005,28(5):480-482. 被引量:17
  • 7王全晖,高春芳,王秀丽,赵光,李冬晖.大肠癌手术治疗前后血清蛋白质谱的变化[J].中华实验外科杂志,2004,21(7):804-806. 被引量:5
  • 8Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet, 2002,359: 572-577.
  • 9邹伟,辛晓燕.血清蛋白质图谱分析在卵巢癌早期诊断中的应用[J].国外医学(妇幼保健分册),2003,14(6):420-422. 被引量:1
  • 10Vuadens F, Benay C, Crettaz D,et al. Identification of biologic markers of the premature rupture of fetal membranes: proteomic approach. Proteomics, 2003,3 : 1521-1525.

二级参考文献33

  • 1[1]Ozols R F, Rubin S C, Thomas G M, et al. Epithelial ovarian cancer. In: Hoskins W J, Perez C A, Young R C, eds. Principles and practice of gynecologic oncology[C]. Philadelphia:Lippincott Williams and Wilkins. 2000: 981 - 1058.
  • 2[2]Menon U, Jacobs I. Recent developments in ovarian cancer screening[ J ] . Curr Opin Obstet Gynaecol, 2000,12: 39 - 42.
  • 3[3]Rosenthal A, Jacobs I. Ovarian cancer screening[J]. Semin Oncol, 1998,25: 315 - 325.
  • 4[4]Cohen L S, Escobar P F, Scharm C, et al. Threedimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction[J]. Gynecol Oncol,2001,82:40- 48.
  • 5[5]Merchant M, Weinberger S R. Recent advancements in surface-enhanced laser desorption/ionization time of fight mass spectrometry[J]. Electrophoresis,2000,21(6):1164- 1177.
  • 6[6]Petricoin E F, Ardekani A M, Hitt B A, et al. Use of proteomic patterns in serum to identify ovarian cancer[J]. Lancet,2002,359: 572 - 577.
  • 7[7]Judith ME, Nancy C, Dolan PC. Update in women's health[J]. Ann Intern Med,2000,133(10) :808- 814.
  • 8[8]Law M R, Morris J K, Wald N J. The importance of age in screening for cancer [ J ] . J Med Screen, 1999,6: 16 - 20.
  • 9[9]Christine H H, Jonathan S B. Ovarian cancer: Epidemiology,biology, and prognostic factors[J] . Seminars in Surgical Oncology,2000,19(1) :3-10.
  • 10[10]Cecile T M, Brekelmans. Risk factors and risk reduction of breast and ovarian cancer[J]. Current Opinion in Obstetrics and Gynecology,2003,15( 1 ) :63 - 68.

共引文献29

同被引文献22

  • 1Michaels JE, Dasari S, Pereira L, et al. Comprehensive proteomic analysis of the human amniotic fluid proteome: gestational age-dependent changes. J Proteome Res,2007, 6 : 1277-1285.
  • 2Queloz PA, Crettaz D, Thadikkaran L, et al. Proteomic analyses of amniotic fluid.. Potential applications in health and diseases. J Chromatogr B Analyt Technol Biomed Life Sci, 2007,850 : 336-342.
  • 3Wang TH, Chang YL, Peng HH, et al. Rapid detection of fetal aneuploidy using proteomics approaches on amniotie fluid supernatant. Prenat Diagn 2005,25 : 559 -566.
  • 4Tsangaris GT, Karamessinis P, Kolialexi A, et al. Proteomic analysis of amniotic fluid in pregnancies with Down syndrome. Proteomics,2006, 6, 4410-4419.
  • 5Mange A, Desmetz C, Bellet V, et al. Proteomic profile determination of autosomal aneuploidies by mass spectrometry on amniotie fluids. Proteome Sci, 2008, 6:1.
  • 6Kolialexi A, Anagnostopoulos AK, Mavrou A, et al. Application of proteomics for diagnosis of fetal aneuploidies and pregnancy complications. J Proteomics, 2009,72 : 731-739.
  • 7Gravett MG, Novy MJ, Rosenfeld RG, et al. Diagnosis of intra-amniotic infection by proteomic profiling and identifiea tion of novel biomarkers. JAMA, 2004,292:462 - 469.
  • 8Buhimschi IA, Zambrano E, Pettker CM, et al. Using proteomic analysis of the human amniotic fluid to identify histologic chorioamnionitis. Obstet Gynecol, 2008,111: 403-412.
  • 9Jacobsson B, Rueschi U, Rosen A, et al. Proteomic analysis using SELDI-TOF-MS in cervical and amniotic fluid to detect biomarkers released in response to intra-inflammation. Am J Obstet Gynecol, 2004, 191 : S108.
  • 10Buhimschi CS, Bhandari V, Hamar BD, et al. Profiling of the Amniotic Fluid to Detect Inflammation, Infection, and Neonatal Sepsis. PLoS Med, 2007,4:e18.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部